Skip to content

Advertisement

Allergy, Asthma & Clinical Immunology

What do you think about BMC? Take part in

Open Access

Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy

Allergy, Asthma & Clinical Immunology201410:20

https://doi.org/10.1186/1710-1492-10-20

Received: 6 January 2014

Accepted: 31 March 2014

Published: 28 April 2014

Abstract

Background

Platelet-activating factor (PAF) is a highly potent phospholipid mediator responsible for the life-threatening manifestations of anaphylaxis. PAF acetylhydrolase (PAF-AH) inactivates PAF and protects against severe anaphylaxis whereas deficiency of PAF-AH predisposes to severe or fatal anaphylaxis. Determinants of PAF-AH activity have not been studied in patients with peanut allergy.

Objectives

To determine whether plasma PAF-AH activity in patients with peanut allergy is related to formation of circulating complexes with apolipoprotein B (apoB) the main surface protein on low density lipoprotein particles.

Methods

Plasma PAF-AH activity and apoB concentrations were measured in 63 peanut allergic patients (35 boys, 28 girls, ages 2 – 19 years). ApoB concentration was measured immunoturbidimetrically using goat anti-human apoB. The correlation between PAF-AH activity and apoB concentration was determined.

Results

A positive correlation was found between PAF-AH activity and apoB concentration (r2 = 0.59, P < 0.0001).

Conclusion

In peanut allergic patients, PAF-AH activity strongly correlates with apoB concentration, suggesting the presence of circulating PAF-AH- lipoprotein complexes.

Keywords

AnaphylaxisPlatelet-activating factor (PAF)PAF-acetylhydrolase (PAF-AH)Low density lipoprotein (LDL)Apolipoprotein B (apoB)

Findings

Deficiency of platelet activating factor acetylhydrolase (PAF-AH) predisposes to severe or fatal anaphylaxis. PAF-AH correlates with apolipoprotein B in peanut allergic patients, suggesting that formation of PAF-AH-lipoprotein complexes is an important determinant of PAF-AH activity.

Introduction

Platelet-activating factor (PAF) is one of the most potent lipid messengers involved in inflammatory events. PAF has been implicated in mediating the life-threatening manifestations of anaphylaxis including hypotension, increased vascular permeability, and severe bronchoconstriction [1, 2]. The association of PAF with severe or fatal anaphylaxis has been observed in both animal models and in humans. PAF receptor antagonists protected against fatal anaphylaxis in experimental animals [3, 4]. PAF receptor knockout mice were resistant to fatal anaphylaxis as compared to wild type mice [5]. In humans, PAF levels correlated more strongly with anaphylaxis severity than did histamine or tryptase [6, 7]. In human vascular smooth muscle cells, epinephrine blocked PAF mediated signaling, likely by phosphorylation of the PAF receptor [8].

Serum PAF concentrations are rigorously controlled by tight regulation of biosynthesis and degradation. Cells synthesize and secrete PAF de novo only when stimulated. De-acetylation of PAF at the sn-2 position terminates the biologic activity of PAF, with formation of the inactive metabolite, lysoPAF [9]. The de-acetylation reaction is catalyzed by PAF acetylhydrolase (PAF-AH), a calcium-independent phospholipase A2 [10]. PAF-AH activity is an important determinant of the circulating half-life of PAF. The half-life of exogenous PAF is significantly longer in sera of PAF-AH deficient persons [6, 11]. Conversely, increasing concentrations of PAF-AH correlate with more rapid inactivation of PAF [6]. Patients deficient in PAF-AH have been shown to be at increased risk of severe or fatal anaphylaxis, although the mechanisms regulating PAF-AH activity in patients at risk for fatal anaphylaxis have not yet been defined [6].

The circulating form of PAF-AH is also known as lipoprotein-associated phospholipase A2. In human plasma, 70% of PAF-AH circulates in fully active form as a complex with low density lipoprotein (LDL) and the remainder in high density lipoproteins (HDL) [12]. Plasma PAF-AH concentration directly correlates with LDL cholesterol concentrations in male subjects [13], such that changes in LDL concentration are reflected by corresponding changes in PAF-AH concentration. The catalytic activity of PAF-AH is regulated by its association with LDL, as lowering LDL in plasma increases the half-life of PAF [13]. The half-life of PAF is also prolonged in patients with abetalipoproteinemia, a condition characterized by deficiency of apolipoprotein-containing lipoproteins, including LDL [13]. Drugs that lower LDL levels lower PAF-AH activity as well. For example, rabbits treated with simvastatin for two months showed decreased PAF-AH activity as compared with control rabbits [14]. Although PAF-AH predominantly circulates in the blood associated with LDL in normolipidemic individuals, the relative proportion of PAF-AH associated with LDL and HDL can be affected by various factors [13]. The relationship between PAF-AH activity and LDL concentrations has not been studied in patients with a history of peanut allergy.

Apolipoprotein B (apoB) is complexed mainly with LDL and is a good surrogate measure of LDL concentration [15]. Generally, more than 90% of plasma apoB is on LDL particles (the remainder on LDL precursors). Each LDL precursor particle has exactly one molecule of apoB on its surface, which remains there during shrinkage to an LDL particle [16]. We undertook this study to investigate whether there is a correlation between PAF-AH activity and apolipoprotein B concentrations in patients with peanut allergy.

Methods

Study design

Apolipoprotein B concentrations and PAF-AH activity were measured in 63 children with peanut allergy (35 boys and 28 girls; mean age, 6.5 ± 3.9 years; range 2–19 years). These children had previous allergic reactions to peanut characterized only by urticaria and/or angioedema with positive skin tests to peanut protein of ≥ 8 mm wheal diameter and/or peanut-specific IgE ≥ 14 kU/L.

The demographics and diagnostic criteria for this patient cohort were reported previously [6]. Informed consent was obtained from all patients or their parents or guardians. This study was approved by the Research Ethics Board of St. Michael’s Hospital.

Reagents

Radiolabelled PAF (1-O-hexadecyl-2-acetyl-H]-sn-glycero-3-phosphoholine, 499.5 Gbq/mmol) was purchased from NEN Life Science Products (Boston, MA). Unlabelled PAF and lyso-PAF were from BIOMOL (Brockville, Ontario). 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine, egg yolk phosphatidylcholine, pefabloc (4-2-[aminoethyl] benzenesulfonyl fluoride) and apolipoprotein-B kit were obtained from Sigma (Oakville, Ontario). Pre-coated TLC plates SILICA GEL 60 (layer thickness 0.25 mm, 20 × 20 cm) were from Merck, Germany. All other chemicals were from Sigma.

Measurement of Apolipoprotein-B concentrations

Plasma PAF-AH activity has been shown to correlate strongly with the plasma concentration of low density lipoproteins (LDL) [10]. PAF-AH activity was measured as a function of apoB concentration. Human apoB concentration was measured immunoturbidimetrically using goat anti-human apoB (Sigma), which forms an insoluble complex resulting in turbidity of the assay mixture. Turbidity was measured spectrophotometrically at 340 nm. The concentration of apoB in the samples was determined from a calibration curve using multiple-level apoB calibrators (Sigma) at 5 different concentrations, ranging from 0–182 mg/dl.

Measurement of PAF-AH activity

PAF-acetylhydrolase activity was measured according to the method of Miwa et al [2] as modified by Vadas et al [6].

Results

PAF-AH and apoB concentrations in patients with peanut allergy

PAF-AH activity and apoB concentrations were measured in 63 peanut allergic patients. The relationship between PAF-AH activity, peanut-specific IgE levels and apoB concentrations is shown in Table 1. PAF-AH activities were plotted as a function of apoB concentrations. Plasma PAF-AH activity was strongly correlated with the plasma concentrations of apoB (r2 = 0.59, P < 0.0001) (Figure 1).
Table 1

PAF-AH, peanut-specific IgE and ApoB concentrations in patients with peanut allergy

 

PAF-AH nmol/min/ml

Peanut-specific IgE KU/L

ApoB mg/dl

Mean

25.18

110.5

50.51

Standard deviation

5.67

270.60

17.17

Standard error

0.7150

34.09

2.163

Lower 95% CI of mean

23.75

42.39

46.18

Upper 95% CI of mean

26.61

178.70

54.83

Figure 1

Scatterplot of PAF-AH activity and apolipoprotein B concentrations.

Discussion

Recently, we reported that in patients with acute allergic reactions, blood PAF levels correlated with severity of anaphylaxis. Patients with the highest levels of circulating PAF had more severe reactions and, conversely, those with lowest PAF levels had least severe reactions [6]. PAF-AH activity correlated inversely with PAF levels and patients with the lowest levels of PAF-AH were at highest risk of severe or fatal anaphylaxis [6]. The odds ratio for patients with severe anaphylaxis vs patients with mild – moderate reactions was 27.0 (95% CI, 4.2-175.5; 2 tailed P = 0.00005 for uncorrected Chi-square) [17]. An odds ratio of 27.0 suggests that patients with the lowest levels of PAF-AH activity were 27.0 times more at risk of severe or fatal anaphylaxis, as compared to patients with normal levels of PAF-AH activity. These and other studies [18] suggest that PAF-AH deficiency predisposes to severe anaphylaxis.

PAF is a potent pro-inflammatory phospholipid messenger which acts via a trans-membrane G-protein coupled PAF receptor [11]. The production of PAF is tightly regulated by both synthetic and degradative processes. Whereas synthesis of PAF in activated cells involves at least 2 enzymes, an arachidonate-specific phospholipase A2 (PLA2) and acetyl-CoA-lyso-PAF acetyltransferase, the degradation of PAF to the biologically inactive form, lyso-PAF, is accomplished by the enzyme PAF-AH. The most likely function of PAF-AH may be that of a safety mechanism to limit the levels of PAF [19].

In contrast to proinflammatory phospholipases [20, 21], PAF-AH is an anti-inflammatory phospholipase that occurs as a plasma isoform complexed mainly with LDL. In a cohort of 240 normolipidemic individuals, plasma PAF-AH activity was strongly correlated with the plasma concentration of LDL [22]. Among normolipidemic individuals, treatment with lovastatin and fenofibrates resulted in proportionate decreases in plasma PAF-AH activity and LDL concentrations [22, 23]. Removal of LDL from the circulation may determine the clearance rate of PAF-AH, modulating the activity of PAF-AH in blood, and thereby influencing the level of PAF [22].

In this study, our aim was to investigate whether PAF-AH activity correlates with apoB, the main surface protein on LDL particles, in patients with peanut allergy. We did find a linear relationship between serum PAF-AH and apoB concentrations throughout the range of PAF-AH activities, in a pediatric patient population. Complex formation with lipoproteins, especially LDL, may, therefore, be an important determinant of PAF-AH activity. Dietary or pharmacologic strategies to lower LDL may have the unintended consequence of altering PAF-AH activity. In particular, lowering LDL levels pharmacologically in patients at risk for anaphylaxis may lower PAF-AH activity in these patients as well, inadvertently leading to an increased risk of severe or fatal anaphylaxis. It remains to be seen if the results reported for a pediatric age group can be extended to adult patients who are most likely to be using lipid lowering drugs. A study of the relationship between use of lipid lowering drugs to severity of anaphylaxis is currently in progress.

Abbreviations

apoB: 

Apolipoprotein B

LDL: 

Low density lipoproteins

PAF-AH: 

Platelet activating factor acetylhydrolase

PAF: 

Platelet activating factor

PLA2: 

Phospholipase A2.

Declarations

Funding

This work was supported by an unrestricted grant to Dr. Peter Vadas from the National Peanut Board.

Authors’ Affiliations

(1)
Division of Allergy and Clinical Immunology, Department of Medicine, St. Michael’s Hospital, University of Toronto

References

  1. Yost CC, Weyrich AS, Zimmerman GA: The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie. 2010, 92 (6): 692-697. 10.1016/j.biochi.2010.02.011.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, Araki Y, Matsumoto M: Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms. J Clin Invest. 1988, 82: 1983-1991. 10.1172/JCI113818.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA: Platelet-activating factor: a mediator for clinicians. J Intern Med. 1995, 238: 5-20. 10.1111/j.1365-2796.1995.tb00894.x.View ArticlePubMedGoogle Scholar
  4. Arias K, Baig M, Colangelo M, Chu D, Walker T, Goncharova S, Coyle A, Vadas P, Waserman S, Jordana M: Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut induced anaphylactic reactions. J Allergy Clin Immunol. 2009, 124: 307-314. 10.1016/j.jaci.2009.03.012.View ArticlePubMedGoogle Scholar
  5. Ishii S, Kuwaki T, Nagase T, Maki K, Tashiro F, Sunaga S, Cao WH, Kume K, Fukuchi Y, Ikuta K, Miyazaki J, Kumada M, Shimizu T: Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med. 1998, 187: 1779-1788. 10.1084/jem.187.11.1779.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, Simons FE, Simons KJ, Cass D, Yeung J: Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. 2008, 358: 28-35. 10.1056/NEJMoa070030.View ArticlePubMedGoogle Scholar
  7. Vadas P, Perelman B, Liss G: Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. J Allergy Clin Immunol. 2013, 131: 144-149. 10.1016/j.jaci.2012.08.016.View ArticlePubMedGoogle Scholar
  8. Vadas P, Perelman B: Effect of epinephrine on platelet-activating-factor-stimulated human vascular smooth muscle cells. J Allergy Clin Immunol. 2012, 129: 1329-1333. 10.1016/j.jaci.2012.02.027.View ArticlePubMedGoogle Scholar
  9. Yanoshita R, Kudo I, Ikizawa K, Chang HW, Kobayashi S, Ohno M, Nojima S, Inoue K: Hydrolysis of platelet activating factor and its methylated analogs by acetylhydrolases. J Biochem. 1988, 103: 815-819.PubMedGoogle Scholar
  10. Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM: Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proc Natl Acad Sci. 1989, 86: 2393-2397. 10.1073/pnas.86.7.2393.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M: Review: plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res. 2003, 42: 93-114. 10.1016/S0163-7827(02)00049-8.View ArticlePubMedGoogle Scholar
  12. Stafforini DM, McIntyre TM, M Carter E, Prescott SM: Human plasma platelet-activating factor acetylhydrolase association with lipoprotein particles and role in the degradation of platelet activating factor. J Biol Chem. 1987, 262: 4215-4222.PubMedGoogle Scholar
  13. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000, 150: 413-419. 10.1016/S0021-9150(99)00406-2.View ArticlePubMedGoogle Scholar
  14. Zhang B, Fan P, Shimoji E, Itabe H, Miura S, Uehara Y, Matsunaga A, Saku K: Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis. 2006, 186: 291-301. 10.1016/j.atherosclerosis.2005.07.029.View ArticlePubMedGoogle Scholar
  15. Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM: Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem. 1999, 274: 7018-7024. 10.1074/jbc.274.11.7018.View ArticlePubMedGoogle Scholar
  16. Fielding PE, Fielding CJ: Dynamics of lipoprotein transport in the human circulatory system. Biochemistry of Lipids, Lipoproteins and Membranes. Edited by: Vance DE, Vance JE. 2002, Amsterdam: Elsevier, 527-552. 4View ArticleGoogle Scholar
  17. Vadas P, Liss G: Anaphylaxis: clinical patterns, mediator release and severity. J Allergy Clin Immunol. 2013Google Scholar
  18. Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, Coulson A, Hartnett L, Nagree Y, Cotterell C, Isbister GK: Anaphylaxis: Clinical patterns, mediator release, and severity. J Allergy Clin Immunol. 2013, 132 (5): 1141-1149. 10.1016/j.jaci.2013.06.015.View ArticlePubMedGoogle Scholar
  19. Gardner AA, Reichert EC, Topham MK, Stafforini DM: Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein. J Biol Chem. 2008, 283: 17099-17106. 10.1074/jbc.M802394200.PubMed CentralView ArticlePubMedGoogle Scholar
  20. Triggiani M, Granata F, Giannattasio G, Marone G: Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. J Allergy Clin Immunol. 2005, 116: 1000-1006. 10.1016/j.jaci.2005.08.011.View ArticlePubMedGoogle Scholar
  21. Vadas P, Browning J, Edelson J, Pruzanski W: Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat. 1993, 8: 1-30.PubMedGoogle Scholar
  22. Guerra R, Zhao B, Mooser V, Stafforini DM, Johnston JM, Cohen JC: Determinants of plasma platelet activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res. 1997, 38: 2281-2288.PubMedGoogle Scholar
  23. Eisaf M, Tselepis AD: Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol. 2003, 66: 2069-2073. 10.1016/S0006-2952(03)00559-8.View ArticlePubMedGoogle Scholar

Copyright

© Perelman et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement